Adrenocortical carcinoma · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Mitotane and EDP Variant #01 Partial | — | R 2 564 | 28d | — | 14.8 mo | 6 | R 15 385 PFS proxy | 1 |
Doxorubicin monotherapy Variant #01 | — | R 902 | 21d | ~6.0 mo | ~8.2 mo | ~9 | ~R 8 114 PFS proxy · indirect | 18 |
Cisplatin and Mitotane Variant #01 Partial | — | R 588 | 21d | — | — | ~26 | ~R 15 296 indirect | — |
Mitotane monotherapy Variant #01 Partial | — | — | 28d | — | — | ~1 | — | — |
Mitotane and Streptozocin Variant #01 Partial | — | — | 21d | — | — | ~2 | — | — |
Placebo Partial | — | — | — | — | — | — | — | 1 |
6 of 6 regimens shown